development Agreement for Multispecific Antibody NM81 in IBD
13/11/2025 11:15
Nov 13 (Reuters) - Kaken Pharmaceutical Co Ltd 4521.T: NUMAB THERAPEUTICS AND KAKEN PHARMACEUTICAL ANNOUNCE LICENSING AND CO-DEVELOPMENT AGREEMENT FOR MULTISPECIFIC ANTIBODY NM81 IN INFLAMMATORY BOWEL DISEASE (IBD) Source text: ID:nGNXbKZZy0 Further company coverage: 4521.T ((reuters.briefs@thomsonreuters.com;))